文献速递前列腺癌泌尿系感染

经直肠前列腺穿刺男性肠道大肠埃希菌抗生素敏感性研究

Antibiotic susceptibility of intestinal Escherichia coli in men undergoing transrectal prostate biopsies: a prospective, registered, multicentre study.
PubMed 文献 · BJU Int · 2018-04-06

这项前瞻性多中心研究纳入359例疑似前列腺癌男性,在经直肠超声引导前列腺穿刺前采集直肠拭子培养大肠埃希菌。结果显示氟喹诺酮耐药和三代头孢耐药菌株占比分别为13%和8%,国际旅行显著增加氟喹诺酮耐药菌株风险。

要点

  • 经直肠穿刺前肠道氟喹诺酮耐药大肠埃希菌占比13%,三代头孢耐药占比8%。
  • 国际旅行使氟喹诺酮耐药大肠埃希菌携带风险显著升高(OR 3.592)。
  • 穿刺后感染防治需考虑当代抗生素耐药形势。

核心结论

  • 芬兰经直肠前列腺穿刺男性肠道氟喹诺酮耐药和/或三代头孢耐药(潜在产ESBL)大肠埃希菌携带率值得关注。
  • 国际旅行是携带肠道氟喹诺酮耐药大肠埃希菌的明确危险因素。
  • 经直肠穿刺后感染的防治应结合当代抗生素耐药情况。

研究设计与样本

  • 前瞻性、注册、多中心研究,为multi-IMPROD试验(NCT02241122)的子研究。
  • 纳入4个中心共359例疑似前列腺癌男性,穿刺前完成问卷并采集直肠拭子培养大肠埃希菌。
  • 采用单因素和多因素logistic回归分析氟喹诺酮耐药或三代头孢耐药大肠埃希菌的危险因素。

主要发现

  • 研究人群中氟喹诺酮耐药大肠埃希菌占比13%,三代头孢耐药占比8%。
  • 在大肠埃希菌阳性患者中,氟喹诺酮耐药和三代头孢耐药菌株占比分别为14%和8%。
  • 三代头孢耐药菌株中62%为ESBL产生菌,88%同时氟喹诺酮耐药。
  • 多因素分析显示,过去一年国际旅行显著增加氟喹诺酮耐药大肠埃希菌携带风险(OR 3.592,P=0.001)。
  • 过去一年使用抗生素显著降低氟喹诺酮耐药大肠埃希菌携带风险(OR 0.442,P=0.035)。

关键数值与推荐

  • 氟喹诺酮耐药大肠埃希菌危险因素:过去一年国际旅行(OR 3.592,P=0.001)。
  • 氟喹诺酮耐药大肠埃希菌保护因素:过去一年使用抗生素(OR 0.442,P=0.035)。
  • 未发现三代头孢耐药大肠埃希菌的显著危险因素。

临床怎么用

  • 经直肠前列腺穿刺前应评估患者国际旅行史和近期抗生素使用史。
  • 穿刺后感染的经验性抗生素选择需考虑氟喹诺酮和三代头孢耐药大肠埃希菌的局部流行情况。
  • 对高风险患者可考虑调整穿刺途径或预防性抗生素方案。

局限性

  • 本研究为观察性研究,无法确立因果关系。
  • 研究仅在芬兰进行,结果外推需谨慎。
  • 未发现三代头孢耐药大肠埃希菌的显著危险因素,可能受样本量限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine, in a prospective, multicentre setting, the prevalence of fluoroquinolone-resistant (FQ-R) and extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (E. coli) strains in men undergoing transrectal ultrasonography-guided prostate biopsy (TRUS-Bx) in Finland; and to survey the associated risk factors for having the previously mentioned strains. PATIENTS AND METHODS: This is a substudy of the trial investigating the role of magnetic resonance imaging (MRI) in prostate cancer diagnosis (Improved Prostate Cancer Diagnosis - Combination of Magnetic Resonance Imaging Targeted Biopsies and Biomarkers Multi-institutional Study [multi-IMPROD], NCT02241122). In all, 359 patients from four study centres were recruited to this prospective study. After having signed the informed consent form, these men with suspicion of prostate cancer completed a detailed questionnaire on their medical, smoking, and travelling history, as well as their recent use of antibiotics. After the bi-parametric MRI scan, TRUS-Bx was taken and a rectal swab sample was collected and cultured for determining the antimicrobial susceptibility profile of E. coli strains. The potential risk factors for having FQ-R or third-generation cephalosporin-resistant (3GC-R) E. coli strains were analysed using univariate and multivariate logistic regression analysis. RESULTS: The percentage of FQ-R and 3GC-R E. coli strains amongst the study population was 13% and 8%, respectively. Amongst patients having E. coli strains, the rate of FQ-R and 3GC-R strains was 14% and 8%, respectively. Of the 3GC-R E. coli strains, 62% proved to be ESBL-producers and 88% were also FQ-R. In multivariate analysis, international travel during the preceding year significantly increased the risk of having a FQ-R E. coli strain (odds ratio [OR] 3.592, P = 0.001) and, unexpectedly, use of antibiotics during the previous year significantly decreased this risk (OR 0.442, P = 0.035). No significant risk factors for having 3GC-R E. coli were identified. CONCLUSION: The occurrence of intestinal FQ-R and/or 3GC-R (potentially ESBL-producing) E. coli strains in men undergoing TRUS-Bx in Finland is notable. The finding is consistent with the global increase in antimicrobial resistance. International travel appears to be an indisputable risk factor for having intestinal FQ-R E. coli strains. The contemporary antimicrobial resistance situation should be taken into account in the care of post-TRUS-Bx infections.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Knaapila J, Kallio H, Hakanen AJ, et al. Antibiotic susceptibility of intestinal Escherichia coli in men undergoing transrectal prostate biopsies: a prospective, registered, multicentre study. BJU Int. 2018. PMID: 29533507. doi:10.1111/bju.14198

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。